Search clinical trials for: bimatoprost formulation A solution

Total 969 results

Allergan

Completed

Bimatoprost in the Treatment of Eyelash Hypotrichosis

Idiopathic Eyelash Hypotrichosis

Russian Federation, Sweden, United States, United Kingdom
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

Alopecia | Baldness

United States, Germany
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

Alopecia | Alopecia, Androgenetic | Baldness

United States, Germany
Allergan

Completed

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

Androgenetic Alopecia

United States
Allergan

Completed

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

Alopecia | Alopecia, Androgenetic | Baldness

United States
Allergan

Completed

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Allergan

Terminated

A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma

Glaucoma

United Kingdom, Taiwan, Korea, Republic of, United States, Italy, Philippines, France
Singapore National Eye Centre
Allergan

Unknown

Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study

Glaucoma, Angle-Closure

Singapore
Allergan

Completed

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, Czech Republic, Germany, Russian Federation, Hungary, Australia, Israel, United Kingdom, United States
Allergan

Completed

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

Alopecia | Alopecia, Androgenetic | Baldness

United States
Allergan

Completed

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

Eyelash Hypotrichosis

United States
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Bimatoprost for the Treatment of Eyebrow Hypotrichosis

Eyebrow Hypotrichosis

United States, Canada
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis

Eyelash Hypotrichosis

Japan
Allergan

Completed

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Hypotrichosis

United States
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis

Eyelash Hypotrichosis

Japan
Amneal Pharmaceuticals, LLC
CBCC Global Inc.; Amneal EU, Limited

Not yet recruiting

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Ocular Hypertension | Open-angle Glaucoma

United States
Amneal Pharmaceuticals, LLC
CBCC Global Research

Recruiting

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Ocular Hypertension | Glaucoma, Open-Angle

United States
Mankind Pharma Limited
CBCC Global Research

Completed

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma (Glaucoma)

Glaucoma, Open-Angle

United States
ATS Clinical Research
Allergan

Completed

Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows

Hypotrichosis

United States
Jonsson Comprehensive Cancer Center

Withdrawn

Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

Breast Cancer | Alopecia

United States
Allergan

Completed

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

Alopecia Areata | Eyelash Hypotrichosis

United States, Brazil
Allergan

Completed

Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin

Hypotrichosis

United States, United Kingdom
Tulane University
Allergan

Completed

Topical Bimatoprost for Chemical Blepharoplasty

Dermatochalasis

United States
Gian Sagar Medical College and Hospital

Withdrawn

Topical Bimatoprost Solution 0.03%in Stable Vitiligo

Vitiligo | Repigmentation
University of California, San Francisco

Completed

Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata

Alopecia Areata

United States
Allergan

Completed

Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Open-Angle Glaucoma

Belgium
Allergan

Completed

A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons

Ocular Hypertension | Glaucoma, Primary Open Angle

Germany
Allergan

Completed

Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence

Eyelashes

United States, Canada
Manistee Partners

Unknown

Topical Bimatoprost in the Treatment of Migraine

Migraine Disorders | Headache Disorders

United States
Allergan

Completed

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Glaucoma, Open-Angle

Austria
Allergan

Completed

Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis

Hypotrichosis

United States
Allergan

Completed

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Switzerland
Allergan

Completed

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
Alcon Research

Completed

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

Ocular Hypertension | Glaucoma
Allergan

Completed

Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan

Eyelash Hypotrichosis

Japan
AstraZeneca

Completed

Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects (BA)

Healthy Volunteers | Pharmacologic Action

United States
Alcon Research

Completed

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

Ocular Hypertension | Glaucoma | Open-Angle Glaucoma
Allergan

Completed

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Ocular Hypertension | Glaucoma, Open-Angle

United States
Janssen Sciences Ireland UC

Completed

Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants

Healthy

United Kingdom
Allergan

Completed

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Ocular Hypertension | Glaucoma

United States
Alcon Research

Completed

Evaluation of Safety and Tolerability of Ocular Lubricants

Dry Eye

Australia
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US (XLT)

Ocular Hypertension | Glaucoma

United States
Kenneth Beer
Allergan

Completed

Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo

Hypotrichosis

United States
Allergan

Completed

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

United States
Assiut University

Unknown

Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo

Generalized Vitiligo
ViiV Healthcare
GlaxoSmithKline

Not yet recruiting

First Time in Human Study of Long Acting VH4524184 Formulations

HIV Infections

United States
GlaxoSmithKline

Completed

Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients

Multiple Sclerosis

Poland, Germany, Czechia

3

Subscribe